Drug Trial Radar · NCT07629778
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.
Conditions
- Atopic Dermatitis
Interventions
HL-300Drug
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
PlaceboDrug
BID, day 7.
HL-300Drug
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
HL-300Drug
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eczema Area and Severity Index (EASI)Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.